Advertisement
Advertisement
RNXT
RenovoRx, Inc. Common Stock
0.86
USDSponsored
-0.02
-1.87%
May 08, 15:58 UTC -4
Closed
After-Market
0.88
+0.02
+2.36%
RNXT Earnings Reports
Positive Surprise Ratio
RNXT beat 12 of 18 last estimates.
67%
Next Report
In 4 Days
Date of Next Report
May 14, 2026
Estimate for Q1 26 (Revenue/ EPS)
$472.51K
/-$0.08
Implied change from Q4 25 (Revenue/ EPS)
+98.54%
/--
Implied change from Q1 25 (Revenue/ EPS)
+139.86%
/--
RenovoRx, Inc. Common Stock earnings per share and revenue
On Mar 30, 2026, RNXT reported earnings of -0.08 USD per share (EPS) for Q4 25, beating the estimate of -0.08 USD, resulting in a 1.96% surprise. Revenue reached 238.00 thousand, compared to an expected 428.14 thousand, with a -44.41% difference. The market reacted with a -5.61% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 472.51 thousand USD, implying an increase of 0.00% EPS, and increase of 98.54% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
FAQ
What were RenovoRx, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, RenovoRx, Inc. Common Stock reported EPS of -$0.08, beating estimates by 1.96%, and revenue of $238.00K, -44.41% below expectations.
How did the market react to RenovoRx, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -5.61%, changed from $1.07 before the earnings release to $1.01 the day after.
When is RenovoRx, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 14, 2026.
What are the forecasts for RenovoRx, Inc. Common Stock's next earnings report?
Based on 5
analysts, RenovoRx, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of $472.51K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement